Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Smith Kungwankiattichai"'
Publikováno v:
Siriraj Medical Journal. 74:256-265
Objective: This study aimed to validate the sensitivity analysis of all the available formulas for their ability to differentiate between IDA and thalassemia and propose a novel formula to improve the sensitivity of all thalassemia subtypes screening
Autor:
Smith Kungwankiattichai, Weerapat Owattanapanich, Thanawat Rattanathammethee, Ekarat Rattarittamrong, Chantiya Chanswangphuwana, Chantana Polprasert, Wasithep Limvorapitak, Supawee Saengboon, Pimjai Niparuck, Teeraya Puavilai, Jakrawadee Julamanee, Pirun Saelue, Chinadol Wanitpongpun, Kannadit Prayongratana, Chantarapa Sriswasdi, Chajchawan Nakhakes
Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML) with a unique clinical presentation and prognosis. This study aimed to investigate the epidemiology, clinical characteristics, treatments, and clinical outcomes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16ada071b51d513783a2231d3ac1acf0
Autor:
Tarinee Rungjirajittranon, Theerapat Siriwannangkul, Smith Kungwankiattichai, Nattawut Leelakanok, Wannaphorn Rotchanapanya, Pongthep Vittayawacharin, Benjamaporn Mekrakseree, Kamolchanok Kulchutisin, Weerapat Owattanapanich
Publikováno v:
Cancers; Volume 14; Issue 21; Pages: 5239
Acute myeloid leukemia (AML) with mutated RUNX1 (RUNX1mut) is considered to have an unfavorable prognosis. However, recent studies have reported comparable survival outcomes with wild-type RUNX1 (RUNX1wt). To assess the clinical outcomes of AML with
Autor:
Chantiya Chanswangphuwana, Chantana Polprasert, Weerapat Owattanapanich, Smith Kungwankiattichai, Adisak Tantiworawit, Thanawat Rattanathammethee, Wasithep Limvorapitak, Supawee Saengboon, Pimjai Niparuck, Teeraya Puavilai, Jakrawadee Julamanee, Pirun Saelue, Chinadol Wanitpongpun, Chajchawan Nakhakes, Kannadit Prayongratana, Chantrapa Sriswasdi
Publikováno v:
Clinical lymphoma, myelomaleukemia. 22(12)
Secondary acute myeloid leukemia (sAML) and AML with myelodysplasia-related changes (AML-MRC) both result in dismal outcomes. This retrospective study aimed to determine whether these features are poor prognostic factors independent of older age and
Autor:
Chantiya Chanswangphuwana, Chantana Polprasert, Weerapat Owattanapanich, Smith Kungwankiattichai, Ekarat Rattarittamrong, Thanawat Rattanathammethee, Wasithep Limvorapitak, Supawee Saengboon, Pimjai Niparuck, Teeraya Puavilai, Jakrawadee Julamanee, Pirun Saelue, Chinadol Wanitpongpun, Chajchawan Nakhakes, Kannadit Prayongratana, Chantrapa Sriswasdi
Publikováno v:
Clinical lymphoma, myelomaleukemia. 22(10)
Intermediate or high doses of cytarabine (IDAC or HiDAC) were recommended as postremission chemotherapy for acute myeloid leukemia (AML). This retrospective study investigated the real-world outcomes of 3-different cytarabine doses from the multicent
Autor:
Smith Kungwankiattichai, Ben Ponvilawan, Claudie Roy, Pattaraporn Tunsing, Florian Kuchenbauer, Weerapat Owattanapanich
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
IntroductionHypomethylating agents (HMAs) seem to have a range of properties favorable to post-allogeneic hematopoietic stem cell transplantation (allo-SCT) maintenance in acute myeloid leukemia (AML) patients.Materials and MethodsThe Embase, MEDLINE
Autor:
Tarinee Rungjirajittranon, Theerapat Siriwannangkul, Nattawut Leelakanok, Smith Kungwankiattichai, Wannaphorn Rotchanapanya, Pongthep Vittayawacharin, Benjamaporn Mekrakseree, Kamolchanok Kulchutisin, Weerapat Owattanapanich
Publikováno v:
Blood. 140:3222-3222
Autor:
Pattaraporn Tunsing, Smith Kungwankiattichai, Ben Ponvilawa, Florian Kuchenbauer, Claudie Roy, Weerapat Owattanapanich
Review question / Objective: P: Patients with AML or MDS after allo-SCT; I: Hypomethylating agents after allo-SCT; C: Observation after allo-SCT; O: Overall survival rates. Condition being studied: Hypomethylating agents (HMAs) seem to have a range o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d58dd334f1d582c5b4d6f451c66cb3c6
https://doi.org/10.37766/inplasy2021.11.0078
https://doi.org/10.37766/inplasy2021.11.0078
Publikováno v:
Hematology/Oncology and Stem Cell Therapy.
Background Matched donor (MD) allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the preferred choice of treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients who have achieved complet
Autor:
Weerapat Owattanapanich, Smith Kungwankiattichai, Chutima Kunacheewa, Tarinee Rungjirajittranon
Publikováno v:
Clinical lymphoma, myelomaleukemia. 21(12)
BACKGROUND Hypomethylating agent (HMA) is one of recommended treatment for elderly patients with acute myeloid leukemia (AML); however, their high cost precludes their general use, especially in developing countries. Therefore, the fixed-dose HMAs ap